Abstract |
SF-SP which contains sustained release granules of tegafur has been reported to be effective for gastrointestinal and breast cancer. HB-AC, which is an anti-leukemic agent, is known to have considerable activity against a variety of transplanted solid tumors in rats and mice. A comparative clinical study was therefore conducted by randomized controlled trial on the two different chemotherapies, involving as SF-SP group and as SF-SP plus BH-AC group. Among 58 patients, 42 were evaluable for response (SF-SP: 20/30, SF-SP plus BH-AC: 22/28). The partial response rate of SF-SP was 15.0% (3/20) and that of SF-SP plus BH-AC was 13.6% (3/22). The toxicity rates of SF-SP and SF-SP plus BH-AC were 33.3% (10/30) and 36.0% (9/25), respectively. These results indicated that the two therapies were similar in both response and toxicity rates. However, the response appeared faster in the case of SF-SP plus BH-AC therapy than in that of SF-SP therapy.
|
Authors | T Izumi, M Yoshida, T Kamaro, H Sato |
Journal | Gan to kagaku ryoho. Cancer & chemotherapy
(Gan To Kagaku Ryoho)
Vol. 13
Issue 11
Pg. 3215-20
(Oct 1986)
ISSN: 0385-0684 [Print] Japan |
PMID | 3096218
(Publication Type: Clinical Trial, Comparative Study, English Abstract, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Delayed-Action Preparations
- Cytarabine
- Tegafur
- enocitabine
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Colonic Neoplasms
(drug therapy)
- Cytarabine
(administration & dosage, analogs & derivatives)
- Delayed-Action Preparations
- Female
- Humans
- Liver Neoplasms
(drug therapy)
- Male
- Middle Aged
- Splenic Neoplasms
(drug therapy)
- Stomach Neoplasms
(drug therapy)
- Tegafur
(administration & dosage)
|